ARK Genomic Revolution ETF (ARKG)

64.99
Delayed Data
As of Nov 26
 -0.17 / -0.26%
Today’s Change
62.47
Today|||52-Week Range
115.15
-30.31%
Year-to-Date

Investment Objective

The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Performance

1 month-12.92% 3 years+34.67%
3 months-22.20% 5 years+30.20%
1 year-11.94% Since inception+19.40%
Data through 11/25/2021

Quote Details

Previous close$65.16
Open day’s range64.24 – 66.20
Net asset value (NAV)65.20 (11/24/2021)
Daily volume2,391,592
Average volume (3 months)2,191,533
Data as of 1:34pm ET, 11/26/2021

Peer Comparisonvs. Health ETFs

 ARKGCategory
Performance 5-yr return+30.20%+13.75%
Expense Gross exp ratio0.75%1.00%
Risk 5 year sharpe ratio1.060.91
Net assets$7.2B$2.4B
Average market cap$7.1B$37.7B
Average P/E--25.0
Dividend / Share--0.29%

Competitors

RYH Invesco S&P 500® Equal Weight Health Ca...
VHT Vanguard Health Care Index Fund ETF Shar...
FHLC Fidelity MSCI Health Care Index ETF

Holdings

Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
TDOC Teladoc Health Inc8.93%
EXAS Exact Sciences Corp5.43%
PACB Pacific Biosciences of California Inc5.30%
IONS Ionis Pharmaceuticals Inc3.76%
VRTX Vertex Pharmaceuticals Inc3.74%
TWST Twist Bioscience Corp3.63%
FATE Fate Therapeutics Inc3.57%
NTLA Intellia Therapeutics Inc3.15%
ACCD Accolade Inc3.08%
DNA Ginkgo Bioworks Holdings Inc3.02%